U.S. Condom Market will reach USD 1,680.22 Million by 2022: Zion Market Research
Jan 09, 2017 06:02 am UTC| Business
Sarasota, FL, Jan. 09, 2017 -- Zion Market Research has published a new report titled “Condom Market by Gender (Male and Female), Distribution Channel (Commercial Outlets, Non-commercial Outlets, and Non-traditional...
Jan 09, 2017 06:00 am UTC| Business
MONT-SAINT-GUIBERT, Belgium, Jan. 09, 2017 -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based therapies, announced today that the...
Xenon Pharmaceuticals Outlines Key Milestones for 2017
Jan 09, 2017 01:00 am UTC| Business
BURNABY, British Columbia, Jan. 08, 2017 -- Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone,...
Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
Jan 09, 2017 00:57 am UTC| Business
EMERYVILLE, Calif., Jan. 08, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016 achievements. “We expect 2017 to be a landmark...
Jan 08, 2017 23:00 pm UTC| Business
Enters 2017 with positive momentum for Auryxia® (ferric citrate) in dialysis; preliminary unaudited fourth quarter net U.S. product sales of $8.2 millionSubmitted supplemental new drug application (sNDA) seeking Auryxia...
Jan 08, 2017 21:32 pm UTC| Business
NEW YORK, Jan. 08, 2017 -- Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc. (“TG” or the “Company”) (NASDAQ:TGTX) of the March 7, 2017 deadline to seek the role of...
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
Jan 08, 2017 21:00 pm UTC| Business
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing...